Heart Failure Hospitalization

Among more than 250,000 patients hospitalized for HF for the first time in four countries, more than one-quarter died within 1 year of their hospitalization, according to the EVOLUTION HF cohort study.

Rapid uptitration of medical therapy early after hospitalization for acute HF improves prognosis independent of left ventricular ejection fraction, according to a prespecified analysis of the STRONG-HF trial.

The FDA has approved sotagliflozin, a dual SGLT1/SGLT2 inhibitor, for reduction of risk for death, HF hospitalization and urgent HF visits in patients with HF and in those with certain CV risk factors, Lexicon Pharmaceuticals announced.

Assessing a novel, stick-on thoracic fluid monitor (Microcor, Zoll Medical) for HF management.

After adjusting for factors including use of long-term therapies, the risk for mortality within 30 days of first heart failure hospitalization was between three- and fivefold higher in lower-income vs. higher-income countries, data show.

Patients with heart failure with preserved ejection fraction and those with HF and mildly reduced EF experienced similarly poor outcomes and mortality rates over 12 months follow-up after HF hospitalization, researchers reported.

Alternative anthropometrics, such as waist-to-height ratio, may better predict HF hospitalization and CV death in patients with HF with reduced ejection fraction and overweight compared with BMI alone, researchers reported.

Defining eligibility criteria for initiation of guideline-directed medical therapy and new HF agents.

NEW ORLEANS — A wearable thoracic fluid monitor may be of utility in managing patients with HF and was associated with reduced risk for HF readmission and improved quality of life, a speaker reported.

NEW ORLEANS — The benefits of empagliflozin in patients with HF were consistent regardless of the recency of a patient’s HF hospitalization, researchers reported at the American College of Cardiology Scientific Session.